Last updated on March 2019

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Clinical Study Identifier: NCT03155997

Contact Investigators or Research Sites near you

Start Over

Yasuhiro Yanagita

Gunma Prefectural Cancer Center
Ohta, Japan

Seigo Nakamura

Showa University Hospital
Shinagawa-ku, Japan

Yoshinori Ito

The Cancer Institute Hospital of JFCR
Koto-ku, Japan

Kenji Tamura

National Cancer Center Hospital
Chuo-Ku, Japan

Atsushi Yoshida

St. Lukes International Hospital
Chuo-Ku, Japan

Takashi Ishikawa

Tokyo Medical University Hospital
Shinjuku-ku, Japan

Chikako Shimizu

National Center for Global Health and Medicine
Shinjuku-ku, Japan

Koichiro Tsugawa

St Marianna University School of Medicine Toyoko Hospital
Kawasaki, Japan

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.